For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...

especially warfarin, have become standard treatment for reducing the incidence of strokes and systemic emboli in patients with nonvalvular atrial fibrillation (NVAF). The randomized controlled ...

There is an apparent underuse of warfarin in elderly patients with AF, as there is inconsistency in opinion among clinicians about who should receive anticoagulation. The risks of warfarin are ...

The study was published online in JAMA Neurology on March 31, 2025.

A study led by researchers at the Duke Clinical Research Institute found that just 46 of atrial fibrillation inpatients received a blood thinner at discharge. Disclaimer: AAAS and EurekAlert!

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status.

"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk ...

An NIH-funded clinical trial is exploring the potential role of wearables in managing atrial fibrillation (AFib ... against strokes as continuous anticoagulation. Currently, many AFib patients ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...